Much like our bodies have immune mechanisms to fight off viruses, bacteria have also evolved defenses against phage infections. One such defense are "clustered regularly interspaced short palindromic ...

Bacterial CRISPR–Cas systems provide adaptive immunity against phage by transcribing interfering RNA from phage DNA inserted into the bacterial genome. Using deep-sequencing, the authors detect ...

Like people, bacteria get invaded by viruses. In bacteria, the viral invaders are called bacteriophages, derived from the ...

CRISPR is a double-edged sword. It evolved to help bacteria slay phages. But CRISPR components can also be engineered into phages, arming them against bacteria. Consequently, phage therapy says ...

In some other bacteria, CRISPR is initiated only when infected by a phage. Each CRISPR protein complex contains a different guide RNA from a group of approximately 30 known guide RNAs in this type ...

Model of CRISPR, phage co-evolution explains confusing experimental results. Your friend's email. Your email. I would like to subscribe to Science X Newsletter. Learn more. Your name. Note.

The phage-fighting potency of CRISPR-Cas13 was unexpected given how few microbes use it, explained Adler. The scientists were doubly surprised because the phages it defeated in testing all infect ...

SNIPR001's mechanism of action, as a CRISPR-armed phage therapeutic that specifically targets and eradicates E. coli in the gut, is designed to prevent infections from spreading into the ...

Locus Biosciences, a developer of CRISPR-Cas3-engineered precision antibacterial products, has acquired EpiBiome’s high-throughput bacteriophage phage discovery platform for an undisclosed price ...

As with CRISPR-less phage therapies, clinical trials are needed to determine the treatment's safety profile and appropriate dosing. "I can see these [treatments] coming about in the five- to 10 ...

“The Crispr-enhanced phages allow for degradation of the bacterial genome and would bypass several mechanisms by which bacteria can become resistant to phage,” says Saima Aslam, a professor of ...

As with CRISPR-less phage therapies, clinical trials are needed to determine the treatment's safety profile and appropriate dosing. "I can see these [treatments] coming about in the five- to 10 ...